Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Grows By 57.8%

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 51,300 shares, an increase of 57.8% from the February 13th total of 32,500 shares. Currently, 1.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 66,900 shares, the days-to-cover ratio is currently 0.8 days.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on MNPR shares. Piper Sandler assumed coverage on shares of Monopar Therapeutics in a research note on Friday, January 10th. They issued an "overweight" rating and a $72.00 target price on the stock. HC Wainwright raised their target price on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, January 22nd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MNPR. Janus Henderson Group PLC bought a new position in Monopar Therapeutics in the 4th quarter valued at $23,435,000. Adage Capital Partners GP L.L.C. acquired a new position in Monopar Therapeutics during the 4th quarter worth about $13,182,000. RA Capital Management L.P. acquired a new position in Monopar Therapeutics during the 4th quarter worth about $11,247,000. Point72 Asset Management L.P. bought a new stake in Monopar Therapeutics during the 4th quarter worth about $3,694,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Monopar Therapeutics in the 4th quarter valued at about $2,861,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Monopar Therapeutics Stock Up 0.6 %

NASDAQ:MNPR traded up $0.20 on Tuesday, reaching $34.43. The stock had a trading volume of 17,565 shares, compared to its average volume of 358,996. The company has a market capitalization of $210.09 million, a P/E ratio of -17.48 and a beta of 1.18. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30. The stock has a fifty day moving average price of $35.98 and a 200-day moving average price of $21.76.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.